explore -WSS

explore

author：comprehensive 2025-08-12 06:43:35 - browse：357

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Military medical care influenced by rank and race, new study finds

knowledge

WSS

Venture capitalist Bob Kocher on the state of digital health

Data integrity in scientific journals requires "effort" by publishers, institutions

Readers respond to H5N1 and livestock movements, and more

Appeals court upholds Josh Duggar's conviction for downloading child sex abuse images

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

Anxious about a speech? A startup wants you to pop a minty cardiac drug

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Walensky prepares to leave CDC — and Congress — behind

Solving academic medical centers' existential crisis

Alkermes shareholders re

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

George Santos makes 1st court appearance after pleading not guilty to 13 counts

'The Exorcist' director William Friedkin dead at 87

Drug repurposing or repositioning? The language matters

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Illinois to ban advertising for guns allegedly marketed to kids and militants

hotspot

Appeals court upholds Josh Duggar's conviction for downloading child sex abuse images

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

Biden will tout long

Big Tobacco's 'harm reduction': Is it for real, or a sham?

It's time to retire 'poor historian' from clinicians' vocabularies

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

hotspot

hotspot

knowledge

focus